Gilead Has Outperformed the S&P 500. But is its Valuation Still Attractive?
Gilead Sciences (GILD) stock rose 24% YTD, outperforming the S&P 500. Its forward P/E is 15.5, based on normalized earnings. Q2 2026 revenue grew 10% to $7.8B, with HIV sales up 12%. Gilead gained FDA approvals for Yeztugo and Hepcludex, adding growth drivers.
How this was made
The 30-second read
Why it matters
The FDA approvals provide fresh growth drivers beyond the core HIV franchise, supporting the current valuation multiple.
Market read
Regulatory news for a high‑growth biotech with strong recent performance is likely to move the stock and influence sector sentiment.
What to watch
Potential reimbursement challenges and competition in the HIV space could temper upside.
Background
Gilead has outperformed the S&P 500 YTD, with a 24% gain, and its forward P/E is around 15.5 after adjusting for acquisition charges.
Ticker impact
Gilead received FDA approval for Yeztugo (long‑acting HIV prevention) and accelerated approval for Hepcludex (HDV treatment).
likely upward pressure as investors price in new product revenue potential
FDA clearances add to Gilead's pipeline, especially in high‑growth HIV and HDV markets, and follow a strong YTD performance.
Market effects
Strengthens the biotech/healthcare sector outlook, especially for companies with HIV or viral hepatitis pipelines.
U.S. biotech stocks may see modest gains in early trading.
Adds to global confidence in FDA as a catalyst for biotech valuations.
Counterpoint
If the market has already priced in Gilead's strong YTD rally, the approvals may be a limited catalyst.
Key entities
- companyGilead Sciences, Inc.
US‑listed biopharma (NASDAQ:GILD) focusing on HIV and antiviral therapies.
- regulatorFDA
U.S. Food and Drug Administration, granted approvals for Yeztugo and Hepcludex.
